Some of the most challenging problems in the use of epidemiology for regulatory policy concern summarizing epidemiological and other kinds of information to create a weight of evidence. Another frequent issue is whether to embark on epidemiological study. There are also concerns that negative results never see the light of day. These and other meta-issues are worthy of funded evaluation by expert work groups. -Environ Health Perspect 101 (Suppl 4): 67-69 (1993).
So far we have discussed areas of exposure analysis, study design, and data analysis in which methodological improvements are needed and worthy of research support. For the most part, this support will go to individual researchers to help finance the time spent developing and testing new methods.
In this paper we discuss scientific activities, such as the systematic and consistent summarization of a body of evidence, the decision to initiate more study, and the condusion that enough is enough.
These are issues of risk assessment policy and research strategy, and while not as value laden as risk management (which we do not address in this document), they are by nature a matter of scientific consensus. For this reason, support for the formation of a risk assessment policy often involves development of draft documents by governmental and nongovernmental scientists and the systematic review and development of procedure by groups of researchers. We begin by raising some of the issues of a risk asssessment policy and discuss in the last section how this policy or related research needs could be supported. To place these considerations in context, we must remember that most risk assessment must proceed with only animal data. Therefore, the issues raised here, though important, apply to a small proportion of regulatory decisions. Although epidemiological studies cannot rule out effects of societal concern in this situation, such negative or null studies can sometimes help assess whether humans have higher or lower sensitvity to an agent than expected on the basis of animal bioassays. This is a special topic within the problem of summarizing evidence.
Another problem that often faces those who are trying to weigh a body of evidence is that negative studies (not distinguishable from the null) are thought to be less likely to be published than positive studies. Censoring may occur at the level of the researcher or the journal. For example, a researcher may suggest a positive association between a disease outcome and a variable that was not originally induded in the main hypothesis. The researcher probably would not report a surprising lack of association under the same circumstances. An author whose main hypothesis was not supported in a study may decide not to submit an artide or may become discouraged after receiving routine editorial criticisms. All of this could skew the available evidence. This problem has been discussed previously (4 
Methodological Research Questions
We have raised some research and policy issues that arise when summarizing epidemiological evidence or deciding to initiate new studies in service to the regulatory process. We will briefly discuss them below.
How can funding agencies advance the state of knowledge and the quality of practices in these several areas? As mentioned before, science policy requires a consensus process and, therefore, requires the support of researchers working as a group. Efficiency dictates that some researchers be supported to prepare the 
